Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition.
Topics: Heart Valve, Phase III, Heart, Heart Failure, Pediatric Congenital Heart Disease, clinical trials, Debilitating Diseases, Stemcells, hypoplastic left heart syndrome, Heart Attack, autologousstemcells, heart disease, stemsaveblog
A team of bioengineers from Tel Aviv University is currently developing a scaffold to help regenerate heart muscle through the use of autologous stem cells. The scientists, led by Dr. Tal Dvir, aim to replace damaged cardiac tissue in heart attack patients by creating a scaffold out of collagen and gold nanoparticles, and then infusing it with the patient’s own stem cells to stimulate the rejuvenation of cardiomyocytes.
A team of scientists from the Wyss Institute, Boston Children’s Hospital, and Harvard’s Medical School, Stem Cell Institute, and School of Engineering has created a model to study and develop treatments for the genetic heart disorder Barth Syndrome by utilizing a patient’s own stem cells in conjunction with an organ-on-a-chip. The chip was outfitted with proteins to mimic the cellular environment of the heart, causing the patient’s stem cells to differentiate into diseased heart tissue. The tissue was then studied to not only determine the cause of the disease, but to treat the diseased tissue as well.
Research teams from Cedars-Sinai Heart Institute and the Minneapolis Heart Institute with funding from CIRM [California Institute for Regenerative Medicine] are moving to Phase 2 Clinical Trials for a treatment that utilizes cardiac stem cells to repair severe heart damage. The treatment development was led by Eduardo Marbán, a director at the Cedars-Sinai Heart Institute and founder of Capricor. This groundbreaking treatment involves the injection of stem cells into the coronary artery, which then migrate to the heart and promote the regrowth of healthy heart muscle.
Topics: Heart Valve, Phase III, Heart, Acute Myocardial Infarction, Heart Failure, clinical trials, Debilitating Diseases, Phase II, Stemcells, Heart Attack, autologousstemcells, heart disease, stemsaveblog
Researchers from the University of Vermont have developed a novel and effective application of mesenchymal stem cells [the same type found in Dental Stem Cells] to treat heart disease. The MSCs, when transplanted along with cardiac stem cells into the heart [in an animal model], produced a “cocktail” of protective ligands that improved the grafting success of the cardiac stem cells.
The Cardiovascular Research Foundation will be hosting the Ninth International Conference on Cell Therapy for Cardiovascular Disease from January 22nd to 24th, 2014. The conference will cover major preclinical and clinical studies, as well as the promising stem cell-based products and therapies being developed to treat cardiovascular disease.
The Mayo Clinic, which has been involved in stem cell research and prospective therapies for two decades, reports that we are at the threshold of a medical revolution. By using the body’s own ability to repair and maintain itself, researchers will be able to treat and, in many cases cure, many of today’s most intractable medical conditions. As Dr. Brooks Edwards of the Mayo Clinic explains, “we’re not going to need to wait for a tragic accident and a young person to donate a heart or a liver or a kidney. We’re going to be regenerating those organs. So then if I’m on a transplant list … I’ll be using my cells or some kind of cell-based therapy to either strengthen my own heart, or regenerate my own heart, or even grow a new heart.” Dr. Edwards goes on to predict that solid organ transplants — say, a liver grown from a patient’s own cells — will take place within a decade.